MajorSynthetic opioid, full mu-receptor agonist×Selective serotonin reuptake inhibitors (SSRIs)
Updated · Methodology
Mechanism
Methadone prolongs the QT interval: QT prolongation and torsades de pointes have been reported during treatment, mostly at doses above 100 mg/day (methadone summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Sertraline also prolongs QT, and a dedicated study in healthy volunteers confirmed an exposure-response relationship (sertraline SmPC, AEMPS). Both drugs act on serotonin, and serotonin syndrome can occur when methadone is combined with selective serotonin reuptake inhibitors, SSRIs (methadone SmPC, AEMPS). Sertraline inhibits liver enzymes that clear methadone, so methadone concentrations can rise (methadone label, US Food and Drug Administration, FDA).
Symptoms
An arrhythmia from QT prolongation shows as palpitations, dizziness or fainting. Serotonin syndrome usually starts within hours to a few days of combined use: agitation, hallucinations, fast heart rate, labile blood pressure, fever, overactive reflexes, poor coordination, nausea, vomiting, diarrhea (methadone label, US Food and Drug Administration, FDA). Excess methadone causes sedation and respiratory depression (methadone label, FDA).
Management
The sertraline label of the US Food and Drug Administration (FDA) advises avoiding drugs that prolong the QT interval and lists methadone among them. If the combination is still used, closely monitor cardiac conduction while methadone is started and titrated (methadone label, FDA). Record an electrocardiogram (ECG) before methadone is started, two weeks later and before each dose increase (methadone summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Use both drugs with caution in patients with other risk factors for QT prolongation: heart disease, low potassium or magnesium, slow heart rate, or a family history of QT prolongation or sudden death (sertraline and methadone SmPCs, AEMPS). When sertraline is added to a stable methadone dose, consider reducing the methadone dose until the effect is stable and check often for sedation and slow breathing (methadone label, FDA). After sertraline is stopped, the methadone dose may need to go up (methadone label, FDA). Watch for serotonin syndrome when treatment starts and after dose increases (sertraline label, FDA; sertraline SmPC, AEMPS). If serotonin syndrome is suspected, stop methadone (methadone label, FDA) and consider stopping sertraline (sertraline label, FDA).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- AEMPS: Ficha técnica: Sertralina (nº registro 66057), sección 4.5 (2025)– AEMPS, CIMA, nº registro 66057, sección 4.5
- AEMPS: Ficha técnica: Metadona (nº registro 62423), sección 4.5 (2026)– AEMPS, CIMA, nº registro 62423, sección 4.5
- AEMPS: Ficha técnica: Metadona (Metasedin 40 mg) (nº registro 62423), secciones 4.4 y 4.5 (2026)– AEMPS, CIMA, nº registro 62423, revisión 05/2026, secciones 4.4 y 4.5
- FDA: Zoloft (sertraline hydrochloride) prescribing information (2023)– FDA label, Viatris Specialty LLC, DailyMed setid fda754f6-d0f3-4dce-a17a-927d64f912f7, revised 08/2023, sections 4, 5.2 and 7.1
- AEMPS: Ficha técnica: Sertralina (nº registro 66057), sección 4.4 (2025)– AEMPS, CIMA, nº registro 66057, revisión 08/2025, sección 4.4
- FDA: Methadone hydrochloride tablets (methadone) prescribing information (2025)– FDA, DailyMed setid 4a44bde6-c348-4316-b0e0-c24b407cb823 (VistaPharm), versión 17, revisión 12/2025, secciones 5.4, 5.9 y 7